Modern treatment of breast cancer bone metastases: from bisphosphonates to targeted therapy
The most common site of breast cancer metastases is bone. Bone-targeted therapies with bisphosphonates or denosumab are recommended for all patients with bone metastases of breast cancer. The choice between these two different agents, however, remains open. In this review we discuss the effectiveness of bone-targeted agents, the use of bone turnover markers for treatment decision and efficacy prediction, safety of bisphosphonates and denosumab. We provide a possible therapeutic algorithm and present new agents which are being investigated for the treatment of bone metastases of breast cancer.